Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$6,408 Mln
Revenue (TTM)
$1,125 Mln
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
P/E Ratio
44.3
P/B Ratio
3.9
Industry P/E
--
EV/EBITDA
22.8
Div. Yield
0.3 %
Debt to Equity
0.2
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
49,604,600
CFO
€537.88 Mln
EBITDA
€931.46 Mln
Net Profit
€540.52 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Stevanato Group SpA (STVN)
| 11.5 | 4.2 | 21.3 | 36.7 | 15.5 | -- | -- |
|
BSE Sensex*
| 4.3 | -0.8 | 10.6 | 6.0 | 16.6 | 19.4 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Stevanato Group SpA (STVN)
| 51.9 | -20.0 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.... It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. Read more
Executive Chairman
Mr. Franco Stevanato
CEO & Executive Chairman
Mr. Franco Stevanato
Headquarters
Piombino Dese, PD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Stevanato Group SpA (STVN) stood at $ 2,787 Mln as on 31-Mar-25
The share price of Stevanato Group SpA (STVN) is $24.29 (NYSE) as of 16-Jun-2025 16:10 EDT. Stevanato Group SpA (STVN) has given a return of 15.49% in the last 3 years.
Stevanato Group SpA (STVN) has a market capitalisation of $ 6,408 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Stevanato Group SpA (STVN) is 44.30 times as on 13-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Stevanato Group SpA (STVN) and enter the required number of quantities and click on buy to purchase the shares of Stevanato Group SpA (STVN).
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
The CEO & director of Mr. Franco Stevanato. is Stevanato Group SpA (STVN), and CFO & Sr. VP is Mr. Franco Stevanato.
There is no promoter pledging in Stevanato Group SpA (STVN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Stevanato Group SpA (STVN) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Stevanato Group SpA (STVN) was $0 Mln.
$0.81
(
